Table 2.
LeToHAIC group (n = 71) | Lenvatinib group (n = 86) | p-value | |
---|---|---|---|
Study treatment, median (range) | |||
HAIC cycle | 4 (1–6) | – | |
Toripalimab cycle | 8 (1–17) | – | |
Duration of lenvatinib, months | 9.1 (1.4–16.6) | 4.7 (0.9–16.4) | |
Number of patients who received subsequent treatments | |||
HAIC | 0 | 12 | 0.001 |
Resection | 9 | 0 | 0.001 |
Ablation | 3 | 0 | 0.18 |
Sorafenib | 9 | 17 | 0.23 |
PD-1 antibody | 15* | 40 | 0.001 |
Regorafenib | 20 | 39 | 0.03 |
Transarterial chemoembolization | 13 | 16 | 0.96 |
Radiotherapy | 8 | 5 | 0.22 |
Patient in the LeToHAIC group receive other PD-1 antibodies, such as nivolumab, pembrolizumab, sintilimab, camrelizumab.
HAIC, hepatic arterial infusion chemotherapy; LeToHAIC, lenvatinib, toripalimab plus HAIC; PD-1, programmed cell death protein-1.